157335-93-8

Usage

Uses

Used in Chemical Synthesis:
4,6-Dimethylpyrimidine-5-carboxylic acid is used as a key intermediate in the synthesis of various chemical compounds. Its carboxylic acid group allows for versatile reactions, making it a valuable component in the creation of new molecules and materials.
Used in Research Applications:
In the field of scientific research, 4,6-Dimethylpyrimidine-5-carboxylic acid is employed as a model compound to study the properties and reactivity of pyrimidine derivatives. This helps in understanding the fundamental chemistry of these compounds and their potential applications in various industries.
Used in Pharmaceutical Development:
4,6-Dimethylpyrimidine-5-carboxylic acid is used as a building block in the development of pharmaceuticals, particularly in the design of new drugs. Its chemical structure and reactivity make it a promising candidate for the creation of novel therapeutic agents.
Used in Material Science:
In material science, 4,6-Dimethylpyrimidine-5-carboxylic acid is used to develop new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of substances with tailored characteristics, such as improved stability or enhanced reactivity.

InChI:InChI=1/C7H8N2O2/c1-4-6(7(10)11)5(2)9-3-8-4/h3H,1-2H3,(H,10,11)

Upstream product

• 305794-79-0 4,6-dimethyl-pyrimidine-5-carboxylic acid ethyl ester 
• 544704-02-1 4,6-dimethyl-pyrimidine-5-carboxylic acid tert-butyl ester 
• 7781-20-6 5-bromo-4,6-dimethyl-2(1H)-pyrimidinone 
• 4786-72-5 2-Chloro-5-bromo-4,6-dimethyl-pyrimidine 
• 832090-44-5 methyl 4,6-dimethylpyrimidine-5-carboxylate 
• 157335-96-1 2-hydrazino-4,6-dimethyl-5-bromopyrimidine 
• 544704-01-0 2-acetyl-3-methoxy-but-2-enoic acid tert-butyl ester 
• 603-69-0 ethyl 2-acetylacetoacetate 
• 91179-57-6 tert-butyl 2-acetyl-3-oxobutanoate 
• 69119-22-8 ethyl 2‐acetyl‐3‐methoxybut‐2‐enoate 
• 124-38-9 carbon dioxide 
• 157335-97-2 4,6-dimethyl-5-bromopyrimidine 

Downstream Products

• 306296-10-6 C₃₃H₃₉F₄N₅O 
• 306296-57-1 C₃₃H₃₇F₆N₅O 
• 306296-62-8 (4,6-Dimethyl-pyrimidin-5-yl)-(4-methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone 

Relevant academic research and scientific papers

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo [3.3.0] octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula (I).

Piperazinylpiperidine derivatives as chemokine receptor antagonists

The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR

PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

Pharmaceutical compositions for the treatment of HIV are provided comprising compounds of formula (II) or a pharmaceutically acceptable salt or isomer thereof, in combination with specified antiviral agents.

PROCESS FOR THE PREPARATION AND PURIFICATION OF 2-(ALKOXYALKYLIDENE)-3-KETOALKANOIC ACID ESTERS FROM 3-KETOALKANOIC ACID ESTERS

In its several embodiments, this invention discloses a novel process to prepare the compounds of Formula 3, wherein R1 is lower alkyl, and R2 and R3 can be the same or different, each being independently selected from the group consisting of alkyl, aryl a

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides

The unsymmetrical nicotinamide-N-oxide moiety in compound 1 was replaced with symmetrical isonicotinamides as well as 4,6-dimethyl pyrimidine-5-carboxamides. Compound 16 from the latter set reduced the number of rotamers, improved potency of inhibiting UIV entry, slightly diminished the affinity for the muscarine receptors and showed very good oral absorption.

Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: Synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides

The synthesis, SAR and biological evaluation of symmetrical amide analogues of our clinical candidate SCH 351125 are described. A series of potent and orally bioavailable CCR5 antagonists containing symmetrical 2,6-dimethyl isonicotinamides and 2, 6-dimethyl pyrimidines amides were generated with enhanced affinity for the CCR5 receptor.

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter

Synthesis and Proton NMR Spectra of the Monomethyl- and Dimethylpyrimidine-5-carboxylic Acids. Regioselective Covalent Hydration at the 2- and 4-Ring Positions

Pyrimidine-5-carboxylic acid, its 2-methyl, 4-methyl, 2,4-dimethyl- and 4,6-dimethyl derivatives have been synthesized and their proton nmr spectra measured in dilute aqueous acid.Pyrimidine-5-carboxylic acid (1a, R2,4,6=H) was found to afford an equilibrium mixture of covalent hydrates at both the 2- and 4-ring positions (2a and 3a).The 2-methyl derivative (1b, R2=Me, R4,6=H) undergoes hydration exclusively at the 4-position (2b) while the 4-methyl derivative (1c, R2,6=H, R4=Me) hydrates selectively at only the 2-position (3c).Covalent hydration was notobservable for either the 2,4-dimethyl- (1d, R2,4=Me, R6=H) or 4,6-dimethyl- (1e, R2=H, R4,6=Me) pyrimidinecarboxylic acids.The synthetic routes to these substances are described and the degree of hydration for each compound was measured.